Acadia Pharmaceuticals (ACAD) Gains 7.8% in Four Weeks: Will Wall Street Analysts' Mean Price Target of $29.35 Be a Catalyst for a 27.7% Upside?

Acadia Pharmaceuticals (ACAD) gained 7.8% in the last four weeks and has a 27.7% upside potential according to Wall Street analysts' mean price target of $29.35. The lowest estimate indicates a 26.1% decline, while the most optimistic estimate points to a 69.6% upside. The standard deviation of $5.55 highlights the variability of the estimates. A positive trend in earnings estimate revisions also supports the potential upside in ACAD.